Related by context. All words. (Click for frequent words.) 77 randomization 64 randomized 63 trials RCTs 62 randomized blinded 62 postintervention 61 virologic failure 61 dose titration 61 randomizing 61 timepoints 60 nonrandomized 60 posttreatment 60 blind placebo 60 prospectively stratified 59 prospectively defined 59 virological response 59 blinded randomized 59 F FDG PET 59 titration phase 58 LPV r 58 Kaplan Meier analysis 58 prospective randomized placebo 58 mg kg dose 58 GnRH agonist 58 fibrinolytic therapy 58 noninferiority 58 n = 58 unblinded 58 APTIVUS r 58 bolus dose 58 #:# randomization 58 ancrod 58 dosage regimens 58 periprocedural 58 prespecified 58 virologic response 58 multicenter randomized placebo controlled 57 eptifibatide 57 meta regression 57 conditional logistic regression 57 oral anticoagulation 57 dosing cohorts 57 QTc prolongation 57 randomized controlled trials RCTs 57 alteplase 57 Kaplan Meier curves 57 prespecified secondary 57 genotypic resistance 57 SIMPADICO 57 atazanavir ritonavir 57 fibrinolysis 57 covariate 57 dose escalation phase 56 insulin detemir 56 unfractionated heparin 56 ipsilateral stroke 56 desvenlafaxine succinate 56 binary logistic regression 56 SVR# 56 DAPT 56 doxorubicin docetaxel 56 neoadjuvant chemotherapy 56 #mg QD [001] 56 Dose escalation 56 peginterferon 56 factorial design 56 lymphadenectomy 56 liver biopsies 56 undetectable HBV DNA 56 Thrombolysis 56 p = #.# [003] 56 β blockers 56 active comparator 56 postop 56 RE LY ® 56 factorial 56 percutaneous intervention 56 meta analytic 56 nonoperative 56 logistic regression models 56 darunavir ritonavir 56 antibiotic prophylaxis 56 randomising 56 RE LY 56 Kaplan Meier survival 56 Neuropsychiatric Inventory NPI 56 efficacy evaluable 56 virological failure 56 methotrexate monotherapy 55 oral antidiabetes drugs 55 ICD implantation 55 postprocedure 55 abacavir lamivudine 55 attain statistical significance 55 #mg/day [001] 55 achieved statistical significance 55 clopidogrel pretreatment 55 composite endpoint 55 HCV RESPOND 2 55 label dose titration 55 logistic regression analysis 55 MDRD 55 subanalysis 55 DLTs 55 electrophysiologic 55 warfarin therapy 55 biochemical recurrence 55 Primary endpoints 55 Randomized controlled 55 undergoing coronary angiography 55 androgen suppression 55 FDA defined valvulopathy 55 tipranavir ritonavir 55 DMARD 55 timepoint 55 abciximab 55 mg clopidogrel 55 postoperatively 55 antiandrogen 55 dose escalation 55 oral rivaroxaban 55 logistic regression model 55 BEACOPP 55 randomized crossover 55 postoperative chemotherapy 55 prospective multicentre 55 double blinded placebo 55 rFVIIa 55 preoperative chemotherapy 55 microdose 55 maximal dose 55 coronary revascularization 55 TDF FTC 55 secondary efficacy endpoints 55 prospective randomized multicenter 55 reperfusion therapy 55 androgen ablation 55 randomized #:#:# 55 antiretroviral regimen 55 fondaparinux 55 docetaxel pretreated 55 intraperitoneal 55 anticoagulation therapy 54 adenotonsillectomy 54 IELT 54 mg QD 54 noninferior 54 tumor resection 54 unblinding 54 PASI scores 54 multicentre prospective 54 antiretroviral naive 54 postoperative complication 54 univariate 54 lipid lowering therapy 54 rt PA 54 placebo 54 logistic regression analyzes 54 viral kinetics 54 subgroup analyzes 54 thromboembolic 54 evaluable 54 multicentre randomized 54 ETDRS 54 % CI #.#-#.# [003] 54 randomize 54 electrical cardioversion 54 double blinded randomized 54 reinfarction 54 EURIDIS 54 octreotide LAR 54 NIHSS score 54 elective PCI 54 divalproex sodium 54 undetectable HCV RNA 54 mITT population 54 intravenous cyclophosphamide 54 extubation 54 TURBT 54 XELOX 54 mcg kg 54 Subgroup analysis 54 multivariate Cox 54 nadroparin 54 CR nPR 54 Bonferroni correction 54 chemoradiotherapy 54 antithrombotic therapy 54 goserelin 54 secondary efficacy endpoint 54 dexmedetomidine 54 BoNTA 54 NIHSS 54 pegylated interferon alfa 2b 54 randomized multicentre 54 morphometric vertebral fractures 54 angiographic follow 54 chemoradiation therapy 54 cystectomy 54 Hb A1C 54 reperfusion 54 certolizumab 54 cystoscopic 54 cortical activation 54 saline placebo 54 ARB telmisartan 54 Randomised 54 primary percutaneous coronary 54 blinded placebo 54 multicenter randomized 54 clomipramine 54 MoxDuo TM IR 54 angiographic restenosis 54 mcg albinterferon alfa 2b 54 neoadjuvant 54 eplerenone 54 logistic regression 54 femoral neck fracture 54 multivariable analysis 54 adalimumab 54 seroconversion 53 non inferiority 53 RCTs 53 Percutaneous Coronary Intervention 53 recurrent VTE 53 4mg/kg 53 hypofractionated radiation 53 neoadjuvant therapy 53 Likert scale 53 multicenter randomized controlled 53 sirolimus eluting stents 53 CorVue ™ 53 IFN α 53 triple nucleoside 53 urate lowering therapy 53 crizotinib PF # 53 AMOR IPAT 53 randomise 53 aromatase inhibitor therapy 53 Tumor Response 53 nelfinavir 53 ANOVA 53 concomitant medications 53 NSABP B 53 echocardiographic 53 LEXIVA r 53 Kaplan Meier 53 posttest 53 concurrent chemoradiation 53 nonadherence 53 ANCOVA 53 mg/m2 dose 53 postoperative AF 53 CPAP adherence 53 FDG PET scans 53 MADIT II 53 STRIDE PD 53 retrospective cohort 53 external beam radiotherapy 53 Kaplan Meier estimate 53 mitoxantrone 53 ERCP 53 Subgroup analyzes 53 #mg/m# [002] 53 TAVR 53 multivariate logistic regression 53 polysomnography PSG 53 prospective multicenter 53 flutamide 53 HbA1c levels 53 HIV RNA 53 Kaplan Meier method 53 clinically meaningful improvement 53 tenecteplase 53 preoperative 53 Visual Analogue Scale VAS 53 tumor histology 53 hepatic arterial 53 rFSH 53 neurologic progression 53 MADRS score 53 mg Pycnogenol 53 ritonavir boosted lopinavir 53 dose cohort 53 Randomized 53 DCCT 53 randomized controlled trials 53 unfractionated heparin UFH 53 tapentadol ER 53 FFNS 53 GIK infusion 53 antiarrhythmic drug 53 P = .# 53 QTc 53 antihypertensive therapy 53 glulisine 53 corrected QT interval 53 prospective randomized controlled 53 Pharmacokinetic studies 53 pharmacokinetic PK 53 multivariable Cox 53 DMARD therapy 53 multicentre 53 sustained virological response 53 virologic responses 53 clevidipine 53 relapsed MM 53 ascending dose 53 florbetaben 53 HAQ DI 53 prospective nonrandomized 53 mg dose 53 androgen deprivation 53 radical nephrectomy 53 conjugated equine estrogen 53 XIENCE V demonstrated 53 cilostazol 53 ribavirin RBV 53 prodromal symptoms 53 HBeAg seroconversion 53 paroxysmal AF 53 olanzapine LAI 53 postdischarge 53 pericardial effusion 52 hemoglobin A1c levels 52 pyridostigmine 52 recurrent venous thromboembolism 52 efficacy endpoint 52 evaluable subjects 52 thromboprophylaxis 52 NIH CPSI 52 HCV SPRINT 52 thrombolytic therapy 52 Immunohistochemical analysis 52 #mg QD [002] 52 evaluable patients 52 sirolimus eluting stent 52 NNRTI resistance 52 ug dose 52 #mg BID [001] 52 actigraphy 52 zolmitriptan 52 adjuvant tamoxifen 52 Edge STudy 52 R# #mg BID 52 BRIM3 52 irbesartan 52 tamoxifen therapy 52 randomized multicenter 52 olmesartan 52 prospective multicenter study 52 PREZISTA r 52 hematologic toxicity 52 treatment naive genotype 52 enfuvirtide 52 radical cystectomy 52 VADT 52 symptomatic VTE 52 hyperinsulinemic euglycemic clamp 52 #mg/day [002] 52 NCT# ClinicalTrials.gov 52 tolvaptan 52 GOUT 52 efavirenz EFV 52 patients evaluable 52 PRIMO CABG 52 nephrectomy 52 deferoxamine 52 tamsulosin 52 multiple logistic regression 52 SSRI SNRI 52 PREVENT IV 52 postdose 52 beta blocker therapy 52 revascularizations 52 TAXUS ARRIVE 52 mL kg 52 bosentan 52 Phase III VISTA 52 biochemical relapse 52 LVEF 52 adjuvant trastuzumab 52 femoral shaft fracture 52 lumbar spine BMD 52 Randomized Evaluation 52 rebleeding 52 ALLHAT 52 Stenting Trial CREST 52 YMRS 52 Val HeFT 52 CATIE AD 52 idraparinux 52 NYHA functional class 52 posttransplant 52 tacrolimus ointment 52 NSTE ACS 52 HF ACTION 52 ABVD 52 CANCIDAS 52 edifoligide 52 virologic breakthrough 52 Major Adverse Cardiac 52 pegnivacogin 52 paclitaxel eluting stents 52 sonographic examinations 52 everolimus eluting stents 52 clopidogrel 52 sirolimus stent 52 ACTIVE W 52 infliximab 52 drug eluting stent implantation 52 abatacept 52 nonfatal MI 52 plasma cortisol 52 LNG IUS 52 virologic 52 nortriptyline 52 EMPHASIS HF trial 52 preoperative intraoperative 52 EVEREST II 52 cluster randomized controlled 52 teriflunomide 52 SUVmax 52 platelet reactivity 52 EmbraceAC 52 hemoglobin A1c HbA1c 52 nadolol 52 median PFS 52 LCP AtorFen 52 angiographic 52 pharmacokinetic characteristics 52 QTc intervals 52 progression TTP 52 randomized controlled trial 52 blinded randomized controlled 52 primary efficacy endpoint 52 definite stent thrombosis 52 estimated GFR 52 Meta analyzes 52 modified REGENESIS Phase IIb 52 stavudine d4T 52 avosentan 52 stepwise logistic regression 52 multivariate analyzes 52 solifenacin 52 TEAEs 52 Secondary efficacy endpoints 52 amoxicillin clavulanate 52 intravitreal injection 52 Elitek 52 μmol L 52 predefined criteria 52 biventricular repair 52 docetaxel prednisone 52 randomized #:# 52 cerebrovascular events 52 FDG-PET/CT 52 6MWD 52 pharmacokinetics PK 52 placebo controlled randomized 52 receiving VICTRELIS 52 endoscopic gastric ulcers 52 pegaptanib 52 zonisamide SR 52 interobserver 52 intraocular inflammation 52 QRS duration 52 NNT = 52 generalized estimating 52 FOLFIRI alone 52 pairwise comparisons 52 pCR 52 BENICAR HCT 52 dosing cohort 52 placebo controlled clinical 52 salmeterol fluticasone 52 nonresponders 52 NATRECOR R 52 ALT flares 52 PEARL SC 52 postoperative radiotherapy 52 pretest probability 52 telaprevir dosing 52 TACE 52 Poisson regression 52 Secondary endpoints included 52 bupropion SR 52 sentinel lymph node biopsy 52 RECIST criteria 52 NRTI 51 endometrial thickness 51 pneumonectomy 51 detectable HCV RNA 51 adjuvant radiotherapy 51 creatinine clearance 51 oxycodone CR 51 adefovir treated 51 atorvastatin #mg 51 oocytes retrieved 51 moderately emetogenic 51 chlorambucil 51 Brief Psychiatric 51 rotigotine 51 dosing interval 51 transfemoral 51 antiretroviral naïve 51 placebo controlled trials 51 hip BMD 51 prazosin 51 bezafibrate 51 intradermal injections 51 adenoma recurrence 51 postoperative mortality 51 RARP 51 debulking surgery 51 liver transplant recipients 51 confidence interval CI 51 secondary endpoint 51 periprocedural MI 51 euglycemic clamp 51 peg IFN 51 sinus rhythm 51 tumor necrosis 51 vasogenic edema 51 resynchronization therapy 51 intact parathyroid hormone 51 locoregional recurrence 51 multivariable logistic regression 51 asthma exacerbation 51 amisulpride 51 Tmax 51 intravenous dosing 51 syndromal 51 QTcF 51 WOMAC pain 51 #mg dosing 51 hypogonadal men 51 LV dysfunction 51 neurophysiologic 51 tenofovir emtricitabine 51 sternal wound infections 51 LOCF 51 MIRCERA 51 IOP lowering 51 nonoperative treatment 51 FOLPI 51 recanalization 51 multidose 51 urodynamic 51 tirofiban 51 FOLFIRI 51 IV bolus 51 lispro 51 coronary artery stenosis 51 inhaled tobramycin 51 MACCE 51 ABC/3TC 51 gout flares 51 PSA nadir 51 eszopiclone 51 surgical debulking 51 A1c levels 51 entecavir 51 RLAI 51 confidence intervals CIs 51 peri procedural 51 prospective observational 51 ispinesib administered 51 montelukast 51 oral olanzapine 51 Mantel Haenszel 51 cisplatin vinorelbine 51 FOLFOX4 51 prospectively randomized 51 vaginal hysterectomy 51 null responder HCV 51 PLCO 51 Betaferon ® 51 CIMZIA TM certolizumab pegol 51 ACCORD Lipid 51 SCr 51 rHuEPO 51 undetectable viral load 51 arteriography 51 hypofractionated 51 p = NS 51 complete cytogenetic response 51 CsA 51 anticoagulant therapy 51 thrombocytopenic 51 ICD therapy 51 mcg BID 51 BRIM2 51 serum phosphorous 51 nab paclitaxel 51 retest reliability 51 LVSD 51 observational cohort 51 glycated hemoglobin HbA1c 51 renal cysts 51 HAART regimen 51 pretreatment baseline 51 HbA 1c levels 51 tele ICU 51 multivariate regression 51 hepatic resection 51 postmenopausal osteoporotic women 51 intravenous tissue plasminogen 51 transurethral resection 51 multivariable adjustment 51 peginterferon alfa 2b 51 HBeAg negative patients 51 fluorouracil 51 transcranial Doppler 51 chemotherapy docetaxel 51 randomized placebo 51 ultrasonographic 51 HSCT 51 Kruskal Wallis test 51 nulliparous women 51 Platelet counts 51 glycated hemoglobin levels 51 randomized multicenter trial 51 MS DRG 51 randomized trials 51 antimuscarinic 51 intima media thickness IMT 51 bolus injection 51 glycoprotein IIb IIIa inhibitors 51 transcranial Doppler ultrasound 51 Perforomist Inhalation Solution 51 intraperitoneally 51 OADs 51 FOLFOX 51 recurrent ischemia 51 serum HCV RNA 51 HAART regimens 51 placebo controlled clinical trials 51 GAMMAGARD 51 Secondary endpoints 51 Multivariate logistic regression 51 postvaccination 51 PEG IFN 51 endocrine responsive 51 intravenous tPA 51 basal bolus regimen 51 administered subcutaneously 51 hours postdose 51 diameter stenosis 51 intravascular ultrasonography 51 pegylated liposomal doxorubicin 51 intravitreal injections 51 multicenter prospective 51 plus ribavirin 51 Teriflunomide 51 Secondary endpoints include 51 Edwards SAPIEN valve 51 radiographic progression 51 ibandronate 51 p = 51 serum phosphorus 51 CTEPH 51 triamcinolone 51 GSK# [001] 51 Vacc 4x 51 pharmacodynamic PD 51 pimecrolimus cream 51 adjuvant chemotherapy 51 infarct size 51 #mg doses [002] 51 Butrans 51 Logistic regression analyzes 51 EQ 5D 51 curative resection 51 Phase III randomized controlled 51 otamixaban 51 intravenous bolus 51 PANSS 51 confounding variables 51 liver resection 51 tumor regressions 51 total knee arthroplasty 51 surrogate endpoint 51 Zevalin consolidation 51 relapsed MCL 51 carotid artery stenting CAS 51 mCi kg 51 sleeve lobectomy 51 8mg/kg 50 sustained virologic response 50 covariates 50 Free Survival PFS 50 quetiapine 50 IV NSCLC 50 enoxaparin 50 CSBM 50 cortical stimulation 50 Pain Intensity 50 plasma uric acid 50 weekly subcutaneous injections 50 MetS 50 Pred Forte 50 hepatectomy 50 5-FU/LV 50 HAM D# 50 antiangiogenic therapy 50 VELCADE melphalan 50 paricalcitol 50 MMSE score 50 Baseline characteristics 50 ABSORB trial 50 ximelagatran 50 graft patency 50 IMPACT DCM 50 nonmetastatic prostate cancer 50 oncologic outcomes 50 interquartile range 50 dose proportionality 50 Operative mortality 50 MGd 50 SLNB 50 antimicrobial prophylaxis 50 adjunctive placebo 50 NATRECOR ® 50 CORE OM 50 antithrombotics 50 blind multicentre 50 observational cohort study 50 DAS# CRP 50 mg RDEA# 50 Phase III randomized placebo 50 oral prednisolone 50 haemodynamic 50 DAS# scores 50 cytoreduction 50 antibody titer 50 tipranavir r 50 IQR 50 Postoperatively 50 Peg IFN 50 sirolimus 50 low dose Iluvien 50 serum HBV DNA 50 metastatic HRPC 50 empiric 50 lesional 50 AUA Symptom Score 50 Preoperatively 50 NLX P# 50 LMWH 50 EDSS score 50 aripiprazole 50 IMPROVE HF 50 EBRT 50 Logistic regression 50 remission CR 50 TPV r 50 dorzolamide 50 intravenous IV infusion 50 nonparametric 50 Peg riba 50 STEMI patients 50 exemestane 50 histologically confirmed 50 Pharmacokinetic parameters 50 nonobstructive CAD 50 median sternotomy 50 underwent resection 50 venous thromboembolic disease 50 ischemic lesions 50 nonsignificant 50 oral methylnaltrexone 50 mg kg cohorts 50 dosing 50 FOSRENOL ® 50 CARE HF 50 placebo controlled 50 mg BID 50 CHAMPION PCI 50 lymph node dissection 50 pre operatively 50 retrospective observational study 50 coronary stenosis 50 randomly assigned 50 HbA 1c 50 preintervention 50 ECASS 50 tipranavir 50 placebo dexamethasone 50 IFN beta 50 hemorrhagic complications 50 incontinence episodes 50 CIMZIA ™ 50 chemoradiation 50 prospective randomized 50 gadobutrol 50 antimicrobial susceptibility 50 interferon ribavirin 50 parasitological 50 psychoeducation 50 nonvertebral fractures 50 ExTRACT TIMI 50 clinical pharmacology studies 50 mg simvastatin 50 mITT 50 Serum creatinine 50 oral prednisone 50 pharmacodynamics PD 50 canakinumab 50 glatiramer acetate 50 HORIZONS AMI trial 50 CT perfusion 50 recursive partitioning 50 prospective cohort 50 corticosteroid dose 50 intraclass correlation coefficients 50 SYMMETRY trial 50 UKPDS 50 mcg QD 50 conjugated equine estrogens 50 valvulopathy 50 primary patency 50 RRMS patients 50 left ventricular dysfunction 50 maximal doses 50 dose regimens 50 recurrent glioblastoma multiforme 50 #mg dose [003] 50 neo adjuvant 50 Multiple logistic regression 50 MoxDuo IR 50 lanthanum carbonate 50 univariate analysis 50 preoperatively 50 carotid endarterectomy CEA 50 interrater reliability 50 doxorubicin HCl 50 β blocker 50 BCIRG 50 pramipexole 50 sUA 50 mRCC 50 ENGAGE AF TIMI 50 lamotrigine 50 logistic regressions 50 APTIVUS 50 Flu Cy 50 comparator arm 50 discontinuations 50 statistical significance p 50 serum urate 50 randomized clinical 50 plasma HCV RNA 50 nodular partial response 50 KRAS status 50 histrelin 50 cangrelor 50 radiotherapy RT 50 ziprasidone 50 randomized controlled 50 prospective observational studies 50 TNF inhibitor 50 tecarfarin 50 noninvasive outpatient 50 generalizability 50 q# 50 Postoperative complications 50 serum cortisol 50 SCIg 50 EGFR TKIs 50 intraclass correlation coefficient 50 cerebral angiography 50 lipid lowering drugs 50 pharmacokinetic pharmacodynamic 50 BMD measurements 50 PREZISTA ritonavir 50 intraobserver 50 RAPAFLO R 50 ADAS cog 50 #mg/m# [001] 50 plasma pharmacokinetics 50 concomitant AEDs 50 Treatment Diabetic Retinopathy 50 acetabular fractures 50 mg administered orally 50 pyrazinamide 50 partial remissions 50 Helicobacter pylori eradication 50 axillary node dissection 50 raltegravir 50 #Gy 50 comparator PI r 50 intracoronary 50 thalidomide dexamethasone 50 OPCAB 50 adjuvant therapies 50 histologically proven 50 cytoreductive nephrectomy 50 oral allopurinol 50 M6G 50 confirmed CCyR 50 symptomatology 50 citalopram 50 walk distance 6MWD 50 RESIST studies 50 subcutaneously administered 50 Pegasys plus Copegus 50 premorbid 50 febrile neutropenia 50 atherogenic dyslipidemia 50 Interrater reliability 50 multicenter multinational 50 Vectibix monotherapy 50 resectable 50 inotropic 50 interobserver reliability 50 limiting generalizability 50 TAXUS Stent 50 designated HVTN 50 demonstrated clinically meaningful 50 Montgomery Asberg Depression 50 overnight polysomnography 50 antihyperglycemic 50 TIMI 50 achieved ACR# 50 PRADAXA 50 coronary arteriography 50 perioperatively 50 thoracoscopic lobectomy 50 crossclamp 50 mCi 50 ALGRX 50 p = .# [002] 50 TRITON TIMI 50 sd = 50 prognostic variables 49 rapid virologic response 49 protease inhibitor mutations 49 sub maximal 49 lopinavir r arm 49 polysomnogram 49 locoregional 49 haematologic 49 VcMP 49 Ceplene/IL-2 49 idarubicin 49 eosinophilic asthma 49 tumor progression TTP 49 carboplatin paclitaxel 49 5FU 49 dimensional echocardiography 49 MIRAPEX 49 bupivacaine 49 univariate analyzes 49 rimonabant #mg 49 antiepileptics 49 neutrophil counts 49 suppressive therapy 49 d dimer 49 prospective longitudinal 49 liver metastases 49 HYVET 49 warfarin dosage 49 hypoglycemic events 49 Kaplan Meier curve 49 RE LY trial 49 #mg/kg [002] 49 Polyp Prevention Trial 49 monophasic 49 stent binary restenosis 49 plasma glucose 49 mcg dose 49 perfusion MRI 49 methacholine challenge 49 KRAS mutations occur 49 inhaled budesonide 49 blind randomized 49 elotuzumab 49 lacosamide 49 pharmacodynamic parameters 49 AVERROES 49 antitumor effect 49 revascularization procedures 49 ug kg 49 bivariate 49 nonpharmacologic 49 Cmax 49 mesalamine granules 49 Maximum Tolerated Dose MTD 49 Hypotension 49 REYATAZ ritonavir 49 operable breast cancer 49 mRS 49 hemodilution 49 post hoc 49 PRADAXA #mg 49 placebo controlled dose escalation 49 IPSS 49 surgically induced 49 perioperative mortality